Document:

Exhibit 4.1

 

THIS WARRANT AND THE UNDERLYING
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE
ACT OR UNLESS SUCH TRANSACTION IS IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS.

 

LIFE CARE MEDICAL DEVICES
LIMITED

 

April
9, 2013

 

 

This Certifies That,
for value received, ___________ or his assigns (the “Holder”), is entitled to subscribe for and
purchase from LIFE CARE MEDICAL DEVICES LIMITED, a Nevada corporation (the “Company”), such number
of Exercise Shares as provided herein at the Exercise Price as provided herein. This Warrant is being issued pursuant to the terms
of that certain Convertible Loan Agreement and Promissory Note, of even date herewith, by and among the Company and Holder (the
“Agreement”).

 

1.                 
Definitions. Capitalized terms used but not defined herein
shall have the meanings set forth in the Agreement, as applicable. As used herein, the following terms shall have the following
respective meanings:

 

(a)                                      
“Common Stock” shall mean the common stock of the Company.

 

(b)                                      “Exercise
Period” shall mean the period commencing on the date of issuance of this Warrant and ending three (3) years after
the date of issuance of this Warrant. 

 

(c)                                      “Exercise
Price” of this Warrant shall be $1.00 per share.

 

(d)                                      “Exercise
Share” shall mean each of the fully paid and non-assessable shares of Common Stock for which this Warrant is exercisable.
At the Exercise Price of $1.00 per share, the number of Exercise Shares shall be _______________.

 

2.Exercise
of Warrant. 

 

2.1
Vesting and Exercise. This Warrant will be fully vested and exercisable upon issuance. The rights represented
by this Warrant may be exercised in whole or in part at any time or times during the Exercise Period, by delivery of the following
to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder):

 

		(a)	An executed Notice of Exercise in the form attached hereto;

 

		(b)	Payment of the Exercise Price by wire transfer of immediately
available funds, subject to Paragraph 2.2 below; and

 

		(c)	This Warrant.

 

    	 

    	 	

    
 

Upon the exercise of the rights represented by this Warrant,
a certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or Holder’s designee(s),
shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been
so exercised. In the event that this Warrant is being exercised for less than all of the then-current number of Exercise Shares
purchasable hereunder, the Company shall, concurrently with the issuance by the Company of the number of Exercise Shares for which
this Warrant is then being exercised, issue a new Warrant exercisable for the remaining number of Exercise Shares purchasable hereunder.

 

The person in whose name any certificate or certificates for
Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares
on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery
of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books
of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the
next succeeding date on which the stock transfer books are open.

 

2.2Net (Cashless)
Exercise. Notwithstanding any provisions herein to the contrary, if the fair market value of one Exercise Share is greater
than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash,
the Holder may elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being canceled)
by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which
event the Company shall issue to the Holder a number of Exercise Shares computed using the following formula:

 

X = Y (A-B)

A

 

Where X =   the number of Exercise Shares to be issued
to the Holder

 

	Y =	the number of Exercise Shares purchasable under the Warrant or, if only a portion of the Warrant is being exercised, that portion of the Warrant being canceled (at the date of such calculation)
	 	 
	A =	the fair market value of one Exercise Share (at the date of such calculation)
	 	 
	B =	Exercise Price (as adjusted to the date of such calculation)

 

For purposes of the above calculation, the fair market value
of one Exercise Share shall be (a) the closing price of the Company’s Common Stock on a national securities exchange or the
over-the-counter market on the trading day immediately prior to the date of exercise or (b) if no such market price exists, determined
by the Company’s Board of Directors in good faith; provided, however, that in the event that this Warrant is exercised pursuant
to this Section 2.2 in connection with a public offering of Common Stock, the fair market value per share shall be the per
share offering price to the public in such public offering.

 

    	 

    	 	

    
 

2.3Securities
for Which Warrant is Exercisable.  This Warrant shall be exercisable, in whole or in part, and from time to time, for Common
Stock of the Company.

 

3.Covenants
of the Company.

 

3.1Covenants
as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the
rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and non-assessable, and free
from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the Company
will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of
shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any time during the Exercise
Period the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant,
then, in addition to such other remedies as may be available to Holder, including, without limitation, pursuant to the Note, the
Company will take such corporate action as shall be necessary to increase its authorized but unissued shares of Common Stock to
such number of shares as shall be sufficient for such purposes.

 

3.2Notices of
Record Date. In the event of any taking by the Company of a record of the holders of any class of securities for the purpose
of determining the holders thereof who are entitled to receive any dividend or other distribution, the Company shall mail to the
Holder, at least ten (10) days prior to the applicable date, a notice specifying the date on which any such record is to be taken
for the purpose of such dividend or distribution.

 

3.3No Impairment.
The Holder’s rights, preferences and privileges granted under and/or in connection with this Warrant may not be amended,
modified or waived without the Holder’s prior written consent.

 

3.4Piggyback
Registration Rights. The Holder will be entitled to “piggy-back” registration
rights with respect to the Exercise Shares that are issued pursuant to any exercise of this Warrant, to the extent that capacity
is available in a registration as determined by the Company in its commercially reasonable discretion.

 

4.Representations
of Holder.

 

4.1Acquisition
of Warrant for Personal Account. The Holder represents and warrants that it is acquiring the Warrant and the Exercise Shares
solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares, or
any part thereof, except in compliance with applicable federal and state securities laws. The Holder also represents and warrants
that the all legal and beneficial interests in the Warrant and the Exercise Shares which the Holder is acquiring are being acquired
for, and will be held for, its account only.

 

    	 

    	 	

    
 

4.2Securities
Are Not Registered.

 

(a) The Holder understands
that the Warrant and the Exercise Shares have not been registered under the Act on the basis that no distribution or public offering
of the stock of the Company is to be effected by the Holder. The Holder realizes that the basis for the exemption may not be present
if, notwithstanding its representations, the Holder has a present intention of acquiring the securities for a fixed or determinable
period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing
the securities. The Holder represents and warrants that it has no such present intention.

 

(b) The Holder recognizes
that the Warrant and the Exercise Shares must be held indefinitely unless they are subsequently registered under the Act or an
exemption from such registration is available.

 

(c) The Holder is aware
that neither the Warrant nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions
are met, including, among other things, the availability of certain current public information about the Company, the resale following
the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified
limitations.

 

4.3Disposition
of Warrant and Exercise Shares.

 

The Holder understands
and agrees that any Exercise Shares issued pursuant to exercise of this Warrant will not be registered at the time of issuance,
and all certificates evidencing the Shares to be issued to the Holder may bear the following legend:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR UNLESS SUCH TRANSACTION
IS IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS.

 

4.4Accredited
Investor Status. The Holder is an “accredited investor” as defined in Regulation D promulgated under
the Act.

 

5.Adjustment
of Exercise Price and Exercise Shares. 

 

1.1.           
5.1Changes in Securities. In the event of changes in the Common Stock by reason of stock dividends, splits, recapitalizations,
reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the aggregate
number of Exercise Shares then available under the Warrant and the Exercise Price thereof shall be correspondingly adjusted to
give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the same shares as the Holder would have owned
had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring
adjustment. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to
this Warrant. . In case of any merger, consolidation or reorganization of the Company (or any other corporation the stock or securities
of which are at the time receivable upon the exercise of this Warrant) on or after the date hereof, then the Holder, upon the exercise
hereof at any time after the consummation of such change, merger, consolidation or reorganization, shall be entitled to receive,
in lieu of the stock or other securities and property receivable upon the exercise hereof prior to such consummation, the stock
or other securities or property to which such Holder would have been entitled upon such consummation if such holder had exercised
this Warrant immediately prior thereto, and the Exercise Price therefore shall be appropriately adjusted, all subject to further
adjustment as provided in this Section.

 

    	 

    	 	

    
 

6.Fractional
Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant
hereto. All Exercise Shares (including fractions) to be issued upon exercise of this Warrant shall be aggregated for purposes of
determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would
result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise
entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of one
Exercise Share by such fraction.

 

7.Transfer
of Warrant. Subject to applicable laws, this Warrant and all rights hereunder are transferable, in whole or in part,
at any time or times by the Holder, upon delivery of this Warrant and the form of assignment attached hereto to any transferee
designated by Holder and permitted under applicable securities laws. The transferee shall sign a customary investment letter in
form and substance reasonably satisfactory to the Company.

 

8.Lost,
Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on
such terms as to indemnification by the Holder or otherwise as it may reasonably impose (which shall, in the case of a mutilated
Warrant, include the surrender thereof), issue a replacement Warrant of the same denomination and tenor as the Warrant so lost,
stolen, mutilated or destroyed. Upon the issuance of any such replacement Warrant, the original Warrant shall become null and void
without the necessity of any further action on the part of the Company.

 

9.Amendment.
Any term of this Warrant may be amended or waived only with the advance written consent of the Company and the Holder.

 

10.Notices,
etc. All notices required or permitted hereunder shall be in writing and shall be effective upon delivery to the recipient.
All communications shall be sent to the Company and to the Holder at the addresses listed on the signature page hereof or at such
other address as the Company or Holder may designate by written notice to the other parties hereto.

 

11.Governing
Law. This Warrant and all rights, obligations and liabilities hereunder shall be governed by and construed under the
laws of the State of Delaware without giving effect to conflicts of laws principles.

 

[Signature Page Follows]

 

    	 

    	 	

    
 

In Witness Whereof,
the Company has caused this Warrant to be executed by its duly authorized officer as of the date first written above.

 

	 	LIFE CARE MEDICAL DEVICES LIMITED
	 	 
	 	 
	 	By:	 
	 	 	 
	 	Name:	Glenn Foley
	 	 	 
	 	Title:	Chairman and CEO
	 	 	 
	 	Address:	 
	 	 	 	 

 

 

ACKNOWLEDGED AND AGREED:

 

Holder

 

	 	 
	 	 
	 	 

 

    	 

    	 	

    
 

NOTICE
OF EXERCISE

 

TO:
LIFE CARE MEDICAL DEVICES LIMITED

 

(1)      ̈          The undersigned hereby elects to purchase
________ shares of Common Stock (the “Exercise Shares”) of LIFE CARE MEDICAL DEVICES LIMITED (the
“Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise
price in full, together with all applicable transfer taxes, if any.

 

 ̈          The undersigned hereby elects
to purchase ________ shares of Common Stock (the “Exercise Shares”) of LIFE CARE MEDICAL DEVICES LIMITED
(the “Company”) pursuant to the terms of the net exercise provisions set forth in Section 2.1 of
the attached Warrant, and shall tender payment of all applicable transfer taxes, if any.

 

(2)     Please issue a certificate or certificates representing
said Exercise Shares in the name of the undersigned or in such other name as is specified below:

 

________________________

(Name)

 

________________________

________________________

(Address)

 

(3)     The undersigned represents
that (i) the aforesaid Exercise Shares are being acquired for the account of the undersigned for investment and not with a view
to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing
or reselling such shares, except in accordance with applicable federal and state securities laws; (ii) the undersigned is aware
of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach
an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making
investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable
of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) the undersigned
understands that Exercise Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933,
as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions
of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed
herein, and, because such securities have not been registered under the Securities Act, they must be held indefinitely unless subsequently
registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the
aforesaid Exercise Shares may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met
and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use
of the Rule is the availability of current information to the public about the Company; and (vi) the undersigned agrees not to
make any disposition of all or any part of the aforesaid shares of Exercise Shares unless and until there is then in effect a registration
statement under the Securities Act covering such proposed disposition or unless such transaction is in compliance with applicable
federal and state securities laws.

 

    	 

    	 	

    
 

	 	 	 
	(Date)	 	(Signature)
	 	 	 
	 	 	 
	 	 	(Print name)

 

    	 

    	 	

    
 

ASSIGNMENT
FORM

 

(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.)

 

For Value Received,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please Print)
	 	 
	Address:	 
	 	(Please Print)

 

 

Dated: __________, 20__

 

	Holder’s	 	 
	Signature: 	 	 
	 	 	 
	Holder’s	 	 
	Address: 	 	 

 

 

NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations
and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing
Warrant.Exhibit 10.18

 

LIFE CARE MEDICAL DEVICES LIMITED

FORM OF CONVERTIBLE LOAN AGREEMENT and

PROMISSORY NOTE

 

	US $600,000	April 9, 2013 

 

 

1)GENERAL.

 

_______________ (the “Holder”)
hereby grants to Life Care Medical Devices Limited, a Nevada corporation (the “Maker”) a convertible
loan of Six Hundred Thousand Dollars (US$600,000) (the “Loan Amount”) on the terms and conditions set forth
in this Convertible Loan Agreement and Promissory Note (this “Note”). Holder will will deliver the Loan Amount
to Maker upon execution of this Note, in US dollars in immediately available funds, at the account notified to Holder by Maker.
This Note will be payable on August 31, 2013, or such earlier or later date as may be applicable under Sections 2 or 4 hereof.
This Note will bear interest at the rate of twelve percent (12%) per annum, based upon a 360-day year
(the “Interest Amount”). This Note will also bear two hundred percent warrant coverage on the Loan Amount, based
upon a conversion price per share of $0.65, pursuant to the form of Warrant attached hereto as Exhibit A (the “Warrant”).
On or before the Maturity Date, subject to exercise by Holder or its assigns of the conversion rights set forth in Section 5 hereof,
Maker will pay to Holder the Loan Amount and the Interest Amount, in US Dollars in immediately available funds, to the order of
Holder or its assigns, at the account notified to Maker by Holder or its assigns. 

 

2)PRE-PAYMENT.

 

Subject to the conversion rights set forth in Section 5 hereof,
this Note may be pre-paid in whole or in part prior to the Maturity Date (the “Pre-Payment”) at the election
of the Maker in its discretion, provided that in addition to the Principal, the Maker pays the full Repayment Amount that would
have been due at the original Maturity Date.

 

3)DEFAULT PAYMENT.

 

Upon the occurrence of an event of default, after notice and
opportunity for cure as provided in Section 4 hereof (an “Event of Default”), default payments will become due
and payable on any portion of the Repayment Amount that remains unpaid and outstanding after the applicable Maturity Date (the
“Default Principal”). The Default Principal will bear interest from the date of default until repaid, at an
annualized rate of twelve percent (12%) per annum (the “Default Interest Amount”).

 

    	 

    	 	

    
 

4)DEFAULTS.

 

a)Definitions. Each occurrence of any of the
following events will constitute an “Event of Default”:

 

(a)if a default occurs in payment of the Repayment Amount,
or other amounts due under this Note, by the due date thereof, and such default remains uncured for fifteen (15) days from the
date of default;

 

(b)if any representation or warranty of Maker made herein
will have been false or misleading in any material respect, or will have contained any material omission, as of the date hereof;

 

(c)if a default occurs in the due observance or performance
on the part of Maker of any covenant or agreement to be observed or performed pursuant to the terms of this Note and such default
remains uncured for fifteen (15) days thereafter;

 

(d)if Maker (i) discontinues its business, (ii) applies
for or consent to the appointment of a receiver, trustee, custodian or liquidator of Maker or any of its property, (iii) makes
a general assignment for the benefit of creditors, or (iv) files a voluntary petition in bankruptcy, or a petition or an answer
seeking reorganization or an arrangement with creditors, or take advantage of any bankruptcy, reorganization, insolvency, readjustment
of debt, dissolution or liquidation laws or statutes, or file an answer admitting the material allegations of a petition filed
against it in any proceeding under any such law;

 

(e)if there is filed against Maker an involuntary petition
seeking reorganization of Maker or the appointment of a receiver, trustee, custodian or liquidator of Maker or a substantial part
of its assets, or an involuntary petition under any bankruptcy, reorganization or insolvency law of any jurisdiction, whether now
or hereafter in effect (any of the foregoing petitions being hereinafter referred to as an “Involuntary Petition”)
and such Involuntary Petition will not have been dismissed within one hundred twenty (120) days after it was filed;

 

(f)if Maker enters into any agreement, transaction or
undertaking (including, without limitation, any extension or modification of any current or previously existing agreement, transaction
or undertaking) which includes or may include any actual or contingent security interest or other encumbrance upon any of the Maker’s
assets;

 

(g)if Maker enters into any agreement, transaction or
undertaking (including, without limitation, any extension or modification of any current or previously existing agreement, transaction
or undertaking) which includes or may include any actual or contingent anti-dilution or most favored nation provision or arrangement.

 

    	 

    	 	

    
 

4.2Remedies on Default.

 

Upon the occurrence of any Event of Default
and at any time thereafter, Holder may, inter alia, proceed to protect and enforce its rights by an action at law, suit
in equity and/or other appropriate proceeding. No right conferred upon Holder by this Note will be exclusive of any other right
referred to herein or therein or now or hereafter available at law, in equity, by statute or otherwise.

 

5) CONVERSION AND CONVERSION SHARES.

 

5.1 Conversion Election and Notice.
Holder will have the right to elect, in its sole discretion, at any time or times on or before the Maturity Date (or such later
date at which the Repayment Amount is repaid in full), to convert all or any part of the Repayment Amount into common stock of
the Maker (the “Conversion Shares”). Any unconverted portions of the Repayment Amount will be repaid in cash on the
Maturity Date.

 

5.2 Conversion Price, Conversion Shares.
The conversion price of the Conversion Shares (the “Conversion Price”) will be equal to $0.65. In the event
of any stock dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares, or similar actions involving
or affecting the common stock of Maker, the Conversion Price will be correspondingly adjusted. Upon issuance pursuant to this Section
5, the Conversion Shares will be duly authorized, validly issued, fully paid and non-assessable.

 

5.3 Delivery of Conversion Shares.
Maker will deliver the Conversion Shares to Holder within three (3) business days following delivery of a Conversion Notice to
Maker (the “Delivery Date”). Maker understands that a delay in the delivery of Conversion Shares beyond the
applicable Delivery Date could result in economic loss to Holder. As compensation to Holder for such risk, in addition to any other
available remedies at law or equity, Maker agrees to pay late fees to Holder, for delivery of the Conversion Shares after the Delivery
Date, equal to $1,000 per day.

 

5.4 Unregistered
Shares. The Conversion Shares will not be registered upon issuance or within any designated timeframe thereafter under the
Securities Act of 1933, as amended (the “Securities Act”). The certificates evidencing the Conversion Shares
may bear the following legend (or a substantially similar legend) and such other legends as may be required by applicable laws
of any state or foreign jurisdiction (and a stop-transfer order may be placed against transfer of any
such Conversion Shares):

 

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE
ACT OR UNLESS SUCH TRANSACTION IS IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS.”

 

    	 

    	 	

    
 

5.5 Piggy-Back
Registration. Holder will be entitled to “piggy-back” registration rights with respect to the Conversion
Shares, to the extent that capacity is available in a registration, as determined by the Maker in its commercially reasonable discretion.

 

5.6 Transfer of Registration Rights.
The registration rights provided herein may be transferred to any transferee permitted under applicable securities laws, provided
that the Holder provides written notice thereof to the Maker, and provided that the transferee agrees in writing to be bound by
the terms of this Note.

 

5.7 Resale and Transfer of Conversion
Shares. When the Conversion Shares become eligible for resale or transfer, pursuant to Rule 144 or otherwise, the Maker will
pay all fees and expenses (including, without limitation, transfer agent fees and legal fees) associated with (i) the removal of
a legend or stop transfer instructions with respect to the Conversion Shares, and (ii) the issuance of certificates or DWAC registration
to or in the name of the Holder or the Holder’s designee.

 

SECTION 6. MAKER’S REPRESENTATIONS, WARRANTIES AND
COVENANTS.

 

Maker hereby represents,
warrants and covenants the following: 

 

6.1Organization,
Good Standing and Qualification. Maker is a corporation duly organized, validly existing and in good standing under the laws
of Nevada, and has all requisite corporate power and authority to carry on its business. Maker is duly qualified to transact business
and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect on its business,
properties, operations, prospects or condition (financial or otherwise).

 

6.2Authorization.
The execution, delivery and performance by Maker of this Note, and the transactions contemplated hereunder (including, without
limitation, the issuance of common stock pursuant to exercise of the Warrant), have been duly authorized by all requisite corporate
action by Maker in accordance with applicable law. This Note is a valid and binding obligation of Maker, enforceable against Maker
in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, or other laws
of general application affecting enforcements of creditors’ rights or general principles of equity.

 

6.3No
Conflicts. The execution, delivery, performance, issuance, sale and delivery of this Note and compliance with the provisions
hereof by Maker will not, to the knowledge of Maker, (a) violate any provision of any law, statute, rule or regulation applicable
to Maker or any order, judgment or decree of any court, arbitrator, administrative agency or other governmental body applicable
to Maker or any of its assets or (b) conflict with or result in any material breach of any of the terms or conditions of any agreement
or instrument to which Maker is a party, or give rise to any right of termination, cancellation or acceleration under any such
agreement or instrument, or result in the creation of any lien or other encumbrance upon any of the material assets of Maker. 

 

6.4 Authorized Shares. The Maker
shall take all action necessary to at all times have authorized and available for issuance, such number of shares of Common Stock
as shall be necessary to effect the full conversion of all Notes and convertible securities, inclucing Warrants, outstanding at
any time (the “Share Reserve”). If at any time the Share Reserve is insufficient to effect the full conversion
of the Notes, the Maker shall increase the available shares accordingly. If the Maker does not have sufficient authorized and unissued
shares of Common Stock to increase the available shares, the Maker shall call and hold a special meeting of the stockholders as
promptly as practicable, for the purpose of increasing the number of shares authorized.

 

    	 

    	 	

    
 

6.5Compliance with Laws. The
Maker is not in violation of any applicable statute, rule, regulation, order or restriction of any domestic or foreign government
or any instrumentality or agency thereof in respect of the conduct of its business or the ownership of its properties which violation
would materially and adversely affect the business, assets, liabilities, financial condition, operations or prospects of the Maker.
No governmental orders, permissions, consents, approvals or authorizations are required to be obtained and no registrations or
declarations are required to be filed in connection with the execution and delivery of this Note and the issuance of the Warrants
except such as has been duly and validly obtained or filed, or with respect to any filings that must be made after the closing,
as will be filed in a timely manner.

 

6.6Disclosure. All information
relating to or concerning the Maker set forth in this Note by or on behalf of the Maker to the Holder is true and correct in all
material respects, and the Maker has not omitted to state any material fact necessary in order to make the statements made, in
light of the circumstances under which they were made, not misleading. No event or circumstance has occurred or exists with respect
to the Maker or its business, properties, prospects, operations or financial conditions, which under applicable law, rule or regulation,
requires public disclosure or announcement by the Maker and has not been so disclosed or announced.

 

6.6 No Integrated Offering.
Neither the Maker nor any of its affiliates nor any person acting on its or their behalf has made any offer or sales of any security
or solicited any offers to buy any security under circumstances that would eliminate the availability of the exemption from registration
under Rule 506 of Regulation D promulgated under the Securities Act (defined below) in connection with ththis Note and the transactions
contemplated hereby.

 

6.7No Dividends. Maker covenants
that it will not declare or pay any cash dividends on its capital stock so long as any amounts are outstanding under this Note.

 

6.8SEC Reports;
Financial Statements. The Maker has filed all reports, schedules, forms, statements and other documents required to be filed
by the Maker under the Securities Act and the Securities Exchange Act of 1934 (the “Exchange Act”), including pursuant
to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Maker was required
by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated
by reference therein being collectively referred to herein as the “SEC Reports”) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of
their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange
Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The financial statements of the Maker included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at
the time of filing, have been prepared from, and are in accordance with, the books and records of the Maker. Such financial statements
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during
the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Maker as of and for the dates thereof and the results of operations and cash flows
for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

 

    	 

    	 	

    
 

SECTION 7. HOLDER’S REPRESENTATIONS AND WARRANTIES

 

7.1 Accredited Investor. Holder hereby
represents and warrants that Holder has substantial experience in evaluating and investing in securities, and is capable of evaluating
the merits and risks of its loan to Maker under this Note and any investment in Conversion Shares, and has the capacity to protect
its own interests. Holder understands that the loan to Maker pursuant hereto may involve a high degree of risk, and Holder has
the ability withstand the loss of the entire financing amount. Holder is an “accredited investor” within the meaning
of Regulation D under the Securities Act.

 

7.2 Investment Purpose. This
Note is being made for business and investment purposes, and not for household or other purposes. In the event that Holder exercises
any conversion rights pursuant to Section 5 hereof, Holder will be acquiring the Conversion Shares for its own account for
investment only, and not with a view towards distribution. Holder is not aware of publication of any advertisement in connection
with the Conversion Shares.

 

7.3 Unregistered Shares. Holder understands
and agrees that, in the event that it exercises any conversion rights pursuant to Section 5 hereof, the Conversion Shares have
not been and are not being registered under the Securities Act of 1933, as amended (the “Securities Act”), and
may not be transferred unless (A) subsequently registered thereunder, or (B) the Holder shall have delivered to the Maker an opinion
of counsel, reasonably satisfactory in form, scope and substance to the Maker, to the effect that the Conversion Shares to be sold
or transferred may be sold or transferred pursuant to an exemption from such registration. Holder also understands and agrees that
issuance of the Conversion Shares will be pursuant to an exemption from registration contained in the Securities Act based in part
upon Holder’s representations herein. Any sale of the Conversion Shares made in reliance on Rule 144 may be made only in
accordance with the terms of such Rule and further, if such Rule is not applicable, any resale of such Conversion Shares under
circumstances in which the seller, or the person through whom the sale is made, may be deemed to be an underwriter, as that term
is used in the 1933 Act, and/or may require compliance with some other exemption under the 1933 Act or the rules and regulations
of the SEC thereunder. Neither the Maker nor any other person is under any obligation to register the Conversion Shares under the
Securities Act or to comply with the terms and conditions of any exemption thereunder.

 

    	 

    	 	

    
 

7.4 Restrictive Legend. The Holder
acknowledges and agrees that, until such time as the Conversion Shares can be sold without restriction pursuant to Rule 144, the
certificates and other instruments representing any of the Securities shall bear a restrictive legend as provided in Section 5.4
hereof.

 

SECTION 8. COVENANTS

 

8.1 Head Office. So long as this
Note will remain outstanding, Maker will maintain its head office in the United States.

 

8.2 Use of Proceeds. Maker will use
the proceeds from this Note for operating expenses and other obligations of the Maker incurred in pursuing the Maker’s business
plans and strategies inside or outside the U.S. including, without limitation, product rollouts, activities involving facilities
and capacity, research and development expenses, expenses related to regulatory filings and processes with the US Food and Drug
Administration (“FDA”) or with applicable regulators in various countries outside the US, preparations for commercial
delivery of the Maker’s products in various countries outside the US, expenses related to filings and processes with US Securities
and Exchange Commission (“SEC”), expenses related to salaries and other general and administrative operations,
expenses related to litigation, and expenses of accountants, attorneys, consultants and other professionals. Make will not use
the proceeds for the payment of any dividends on its capital stock.

 

SECTION 9. PAYMENTS.

 

9.1 No Discounts
or Setoffs. All payments of principal and interest shall be made without deduction of any present and future taxes,
and without any other right of abatement, reduction, setoff, defense, counterclaim, interruption, deferment or recoupment.

 

9.2 Full Payment Required. The acceptance
by Holder of any sum after the same is due shall not constitute a waiver of the right either to require prompt payment, when due,
of all other sums hereby secured or to declare a subsequent Event of Default as herein provided. The acceptance by Holder of any
sum in an amount less than the sum then due shall be only deemed an acceptance on account and upon condition that it shall not
constitute a waiver of the obligation of Maker to pay the entire sum then due, and failure of Maker to pay such entire sum then
due shall, at the election of Holder, constitute an immediate Event of Default without the necessity for any further notice, notwithstanding
such acceptance of such amount on account. Consent by Holder to any action or inaction of Maker which is subject to consent or
approval of Maker under this Note or any of the other financing documents shall not be deemed a waiver of the right to require
such consent or approval to future or successive actions or inactions.

 

9.3 Business Days. In
the event that the Repayment Amount or any other amounts due under this Note become due and payable on a day other than a business
day, the due date thereof will be extended to the next succeeding business day in the United States. For purposes of the preceding
sentence, a business day will be any day that is not a Saturday or Sunday, or a legal holiday in the State of New York in the United
States. 

 

    	 

    	 	

    
 

SECTION 10. TRANSACTION COSTS; COLLECTION COSTS.

 

10.1 Transaction Costs. Maker agrees
to pay to Holder, upon delivery by Holder of invoices or other supporting documentation, all costs and expenses incurred by or
on behalf of Holder, in connection with this Note, Holder’s underwriting and due diligence with respect to the Note, and
the negotiation, documentation, and closing of the Note (collectively, “Transaction Costs”).

 

10.2 Collection Costs. In the event
that all or part of the indebtedness evidenced by this Note is collected at law or in equity, or in bankruptcy, receivership or
other court proceedings, arbitration or mediation, or any settlement of any of the foregoing, Maker agrees to pay, in addition
to all amounts due and payable hereunder, all costs incurred by Holder in collecting and/or enforcing this Note, including, without
limitation, reasonable attorneys’ fees and expenses.

 

SECTION 11. WAIVERS, DISPUTES, JURISDICTION.

 

11.1Actions of Holder not a Waiver. No delay
by Holder in exercising any power or right hereunder will operate as a waiver of any power or right, nor will any single or partial
exercise of any power or right preclude other or further exercise thereof, or the exercise of any other power or right hereunder
or otherwise; and no waiver or modification of the terms hereof will be valid unless set forth in writing by Holder and then only
to the extent set forth therein.

 

11.2 Consent to Jurisdiction. Maker
hereby submits to the jurisdiction of any state or federal court sitting in the State of Delaware over any suit, action, or proceeding
arising out of or relating to this Note or any other agreements or instruments with respect to Holder. Maker hereby waives, to
the fullest extent permitted by law, any objection that Maker may now or hereafter have to the laying of venue of any such suit,
action, or proceeding brought in any such court and any claim that any such suit, action, or proceeding brought in any such court
has been brought in an inconvenient forum. Final judgment in any such suit, action, or proceeding brought in any such court will
be conclusive and binding upon Maker, and may be enforced in any court in which Maker is subject to jurisdiction by a suit upon
such judgment, provided that service of process is effected upon Maker as provided in this Note or as otherwise permitted by applicable
law. 

 

11.3Waiver of Jury Trial. MAKER WAIVES ANY RIGHTS
IT MAY HAVE TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF THIS NOTE OR ANY DEALINGS BETWEEN MAKER AND HOLDER RELATING
TO THE SUBJECT MATTER OF THIS NOTE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY
BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS NOTE, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT
CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY
OR IN WRITING, AND THIS WAIVER WILL APPLY TO ANY SUBSEQUENT AMENDMENTS, SUPPLEMENTS OR MODIFICATIONS TO THIS NOTE OR TO ANY OTHER
DOCUMENT OR AGREEMENT RELATING TO THE TRANSACTIONS CONTEMPLATED HEREUNDER.

 

    	 

    	 	

    
 

11.4Service of Process. Maker hereby irrevocably
waives personal service of any and all legal process, summons, notices and other documents and other service of process of any
kind and irrevocably consents to such service in any suit, action or proceeding brought in the United States with respect to or
otherwise arising out of or in connection with this Note by any means permitted by applicable law, including by the mailing thereof
(by registered or certified mail, postage prepaid) to the address of Maker specified on the signature page hereto (and shall be
effective when such mailing shall be effective, as provided therein). Refusal to accept delivery, and/or avoidance of delivery,
will be deemed to constitute delivery. Nothing in this Section 11.4 will affect the right of Holder to serve process in any manner
otherwise permitted by law or limit the right of Holder otherwise to bring proceedings against Maker in the courts of any applicable
jurisdiction or jurisdictions. Maker agrees that a final judgment in any such action or proceeding shall be conclusive and may
be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

 

SECTION 12. INDEMNIFICATION.

 

12.1 Indemnification. In consideration
of the financing provided pursutant to this Note, Maker agrees to defend, indemnify and forever hold harmless Holder and its affiliates,
directors, officers, employees, partners, shareholders, members, agents, collaborators, representatives and advisers (collectively,
the “Indemnified Parties”) for, from and against any and all costs, expenses, losses, claims, damages, fees,
penalties and liabilities, joint or several, (collectively, “Costs and Damages”), that may be imposed on, incurred
by or asserted against any Indemnified Parties arising out of, in connection with, or as a result of this Note, the Warrant and
the transactions contemplated hereunder, and/or any prior or subsequent financing of or investment in Maker by or involving Holder
(collectively, the “Indemnified Matters”), including, without limitation, any of the following: (a) the
Note, the Warrant and/or any obligation hereunder, or the use or intended use of the proceeds of this Note, (b) any securities
filings of, or with respect to, Maker; (c) the Maker’s assets and the handling, disposition and/or preservation thereof;
(d) any material inaccuracy or omission in any representation or warranty in this Note or other financing documents; (e) any breach
or failure by Maker to perform its respective obligations hereunder; (f) any actual or prospective investigation, litigation or
other proceeding, whether or not brought by any Indemnififed Party (and including attorneys’ fees in any case), whether or
not any Indemnified Party is a party thereto, and whether or not based on any securities or commercial law or regulation or any
other applicable law or theory thereof, including common law, equity, contract, tort or otherwise; or (g) any other act, event
or transaction related, contemplated in or attendant to any of the foregoing; provided, however, that Maker shall
not have any liability under this Section 12 to any Indemnified Party with respect to any Indemnified Matter to the extent such
liability has resulted primarily from the fraud or willful misconduct of such Indemnified Party, as determined by a court of competent
jurisdiction in a final non-appealable judgment or order, nor shall any Indemnified Party have any liability with respect to any
Indemnified Matter as to which such Indemnified Party would otherwise be liable, except to the extent such liability has resulted
primarily from the gross negligence or willful misconduct of such Indemnified Party, as determined by a court of competent jurisdiction
in a final non-appealable judgment or order. Furthermore, Maker waives and agrees not to assert against any Indemnified Party,
any right of contribution with respect to any Costs and Damages that may be imposed on, incurred by or asserted against any Indemnified
Party.

 

    	 

    	 	

    
 

The Indemnified Parties with the right to
be indemnified under this Section 12 shall have the right to defend any action or proceeding with attorneys of their own selection,
and the Maker shall be solely responsible for all reasonable costs and expenses of such counsel. If the Indemnified Parties opt
not to retain their own counsel, the Maker shall defend any such action or proceeding with attorneys of its choosing at its sole
cost and expense, provided, however, that the Maker may not settle any such action or proceeding without obtaining
the prior written consent of the Indemnified Parties unless such settlement includes a release of the Indemnified Parties which
is comprehensive, unconditional, without restrictions and does not impose obligations on the Indemnified Parties.

 

The indemnification provided hereunder shall
be in addition to (i) any cause of action or similar rights of the Indemnified Parties against the Maker or others, and (ii) any
other liabilities to which the Maker may be subject. The indemnification hereunder, and all representations and warranties made
herein, shall survive the repayment in full of the Repayment Amount and any other amounts due hereunder, and performance of the
obligations hereunder.

 

SECTION 13. MISCELLANEOUS.

 

13.1Notices. All notices, demands and requests
of any kind to be delivered to any party in connection with this Note will be in writing and will be deemed to be effective upon
delivery if (i) personally delivered, (ii) sent by confirmed facsimile or confirmed email with a copy sent by nationally or internationally
recognized overnight courier, (iii) sent by nationally or internationally recognized overnight courier, or (iv) sent by registered
or certified mail, return receipt requested and postage prepaid, addressed as follows:

 

		if to Maker:	Life Care Medical Devices Limited

880 Third Avenue

Suite 905

New York, NY 10022

 

if to Holder:the address set forth below the Holder’s
signature hereto or to such other address as the party to whom notice is to be given may have furnished to the other parties hereto
in writing in accordance with the provisions of this Section.

 

13.2Parties In Interest; Assignment. This Note
will bind and inure to the benefit of Holder, Maker and their respective successors and permitted assigns. Maker will not transfer
or assign this Note without the prior written consent of Holder. Holder may transfer and assign this note without the prior consent
of Maker.

 

    	 

    	 	

    
 

13.3Entire Agreement. This Note contains the
entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements
and understandings among the parties with respect thereto.

 

13.4 Severability. If one or more
provisions of this Note are held to be unenforceable under applicable law, then (i) such provision will be excluded from this Note,
(ii) the balance of the Note will be interpreted as if such provision were so excluded, (iii) the balance of the Note will be enforceable
in accordance with its terms, and (iv) the parties will negotiate in good faith to amend or add to the provisions of this Note
to effectuate as nearly as reasonably practicable, and as nearly as permitted under applicable law, the original intent of the
parties with respect to the provision excluded.

 

13.5Amendments. No provision of this Note may
be amended or waived without the express written consent of both Maker and Holder, provided, however, that Holder may waive any
provision hereof that inures to the benefit of Holder without the prior written consent of Maker.

 

13.6Headings. The section and paragraph headings
contained in this Note are for reference purposes only and will not affect in any way the meaning or interpretation of this Note.

 

13.7Governing Law. This Note will be governed
by and construed in accordance with the laws of the State of Delaware, other than any rules relating to choice of law provided,
however, that nothing in this Note shall limit or restrict the right of Holder to commence any proceeding in any other
jurisdiction as provided in Section 11.4, including, without limitation in any state in which any assets of Maker are located.

 

13.8 Lender-Creditor Relationship.
The relationship between Maker, on the one hand, and Holder, on the other hand, is solely that of lender and creditor. Holder has
no fiduciary relationship or duty to Maker arising out of or in connection with this Note and/or the transactions contemplated
herein, and there is no agency, tenancy or joint venture relationship between Holder and Maker by virtue of this Note and/or the
transactions contemplated therein. None of the Note provisions is intended, nor shall be deemed or construed, to make Holder in
any way responsible for the debts, obligations or losses of Maker. MAKER ACKNOWLEDGES, CONFIRMS AND AGREES THAT HOLDER HAS NOT
ACTED AS AN INVESTMENT, TAX OR FINANCIAL ADVISER TO MAKER IN ANY RESPECT AND HAS NOT OTHERWISE PROVIDED MAKER WITH ANY INVESTMENT,
TAX, OR FINANCIAL ADVICE OF ANY NATURE WHATSOEVER.

 

13.9 Marshalling; Payments Set Aside.
Holder shall have no obligation to marshal any property in favor of Maker or any other person, or against or in payment of any
obligation hereunder. To the extent that Holder receives a payment from Maker pursuant to this Note, from the proceeds of any assets
of Maker, from the exercise of any enforcement action, or otherwise, and such payment is subsequently, in whole or in part, invalidated,
declared to be fraudulent or preferential, set aside or required to be repaid to a trustee, receiver or any other party, then to
the extent of such recovery, the obligation or part thereof originally intended to be satisfied, and all liens, rights and remedies
therefor, shall be revived and continued in full force and effect as if such payment had not occurred.

 

    	 

    	 	

    
 

13.10 Authorization. Maker authorizes
its banks, creditors (including trade creditors), vendors, suppliers, and customers to disclose and release to Holder any and all
information Holder may request from time to time regarding (a) any depository, loan or other credit account of Maker; and (b) the
affairs and financial condition of Maker. Maker also expressly authorizes Holder, from time to time while any of the obligations
hereunder are outstanding, including during any period when a Default exists, to perform background, credit, judgment, lien and
other checks, searches, inspections and investigations and to obtain credit reports and asset reports with respect to Maker and
to answer questions about its credit experience with Maker.

 

13.11 Further Assurances. At any time
and from time to time, upon the written request of Holder and at the sole expense of Maker, Maker shall promptly and duly execute
and deliver any and all such further instruments and documents and take such further action as Holder may reasonably deem necessary
or advisable (a) to obtain the full benefits of this Note and the transactions hereunder; (b) to protect, preserve, maintain and
enforce Holder’s rights in (and the priority of any lien of Holder on) any assets of Maker; or (c) to enable Holder to exercise
all or any of the rights, remedies and powers granted pursuant to this Note.

 

13.12 No Strict Construction. The language
used in this Note and all other documents relating to transactions contemplated herein is the language chosen mutually by the parties
hereto, and no doctrine of construction shall be applied for or against any party.

 

13.13 Counterparts. This Note may be
executed and delivered in any number of counterparts, each of which is an original and which, together, have the same effect as
if each party had signed the same document.

 

13.14 Note Replacement. Upon receipt
by Maker of reasonable evidence of the loss, theft, destruction, or mutilation of this Note, Maker will deliver a new Note containing
the same terms and conditions in lieu of this Note. Any Note delivered in accordance with the provisions of this Section 13 will
be dated as of the date of this Note.

 

[signatures on following page]

 

 

    	 

    	 	

    
 

IN WITNESS WHEREOF, Maker has caused
this Convertible Loan Agreement and Promissory Note to be duly executed by its duly authorized person(s) as of the date first written
above.

 

	MAKER:	 	 	HOLDER:	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	LIFE CARE MEDICAL DEVICES LIMITED	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	By:	 	 	 	By:	 	 
	 	 	 	 	 	 	 
	Name:	Glenn Foley	 	 	Name:	 	 
	 	 	 	 	 	 	 
	Title:	Chairman and CEO	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]